AGO Study Group

What AGO Study Group does

AGO Study Group, operating through its legal entity AGO Research GmbH, is a non-profit academic clinical research organization founded in 1993 and headquartered in Wiesbaden, Germany. The group designs and implements Phase I-III multicenter clinical trials for gynecological oncology indications, with an original focus on ovarian carcinoma (under the name AGO-OVAR) that expanded in 2007 to include cervical, endometrial, vulvar, and rare pelvic tumors in women. Its trials are conducted primarily as Investigator-Initiated Trials (IITs) in accordance with national and international quality standards, leveraging a domestic network of more than 250 university and non-university medical facilities and an international footprint integrated through the Gynecologic Cancer Intergroup (GCIG) and the European Network of Gynaecological Oncology Trial groups (ENGOT).

The organization provides comprehensive clinical trial services across the full study lifecycle: study planning (design, biometrics, sample size, regulatory submissions), study implementation (document preparation, monitoring, SAE/SUSAR management, pharmacovigilance), and study completion (final reports, publications, archiving). These services are delivered in partnership with KKS Marburg for biometrics and quality management, Schantl Pharma Service for monitoring, and MMF for CRO support, with international execution routed through bilateral alliances with NOGGO, GINECO, EORTC, CCTG, NSGO, and GEICO. There are no proprietary software products, AI/ML capabilities, patents, or APIs; the underlying technology is the operational protocol framework and consortium governance that enables multicenter trial execution.

Revenue is generated through professional services fees paid by pharmaceutical and academic sponsors for IIT execution; pricing is not publicly disclosed. The organization is non-profit, has no venture funding, no parent company, and no subsidiaries, and is governed by a Managing Director (Stefanie Barth) with an Executive Board led by Prof. Dr. Philipp Harter as Speaker and Prof. Dr. Sven Mahner as Deputy Speaker, with disease-specific Boards for Ovarian, Uterus, Cervix, Vulva, and Rare Tumors. The customer base spans pharmaceutical companies, academic research institutions, and the patient community participating in trials at the 250+ site network.

Name

AGO Study Group

Legal name

AGO Research GmbH

Website

https://ago-ovar.de

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

AGO Study Group (AGO Research GmbH) is a non-profit academic clinical research organization founded in 1993 in Wiesbaden, Germany, that designs and conducts Phase I-III multicenter trials in gynecological oncology for pharmaceutical sponsors and academic partners through 250+ German sites and the international GCIG/ENGOT network.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)

akta.pro industry

PRIMARYHLAGACAE

Clinical Trial Site Operations & Study Coordination

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

SECONDARYHLAIALAE

Clinical Development (Phase I–III Trial Design & Execution)

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

SECONDARYHLAKAJAD

Gynecologic Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Obstetrics & Gynecology (OB/GYN)

Keywords

• Clinical trial services
• Gynecological oncology research
• Investigator-initiated trials
• Academic research organization
• Multicenter clinical studies

Headquarters

HQ city

Wiesbaden

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Services: The AGO Study Group provides comprehensive clinical trial services including study planning, implementation, and completion for pharmaceutical companies, academic partners, and scientific collaborators. Services include biometrics, monitoring, SAE/SUSAR management, regulatory submissions, and publication support.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

AGO Study Group designs and implements Phase I-III multicenter clinical studies for gynecological oncology indications (ovarian, uterine, cervical, vulvar cancers), typically as Investigator-Initiated Trials (IIT). The organization provides comprehensive clinical trial services spanning study planning (biometrics, monitoring plan, regulatory approvals), study implementation (document preparation, monitoring, SAE/SUSAR management, pharmacovigilance), and study completion (final reports, publications, archiving). Services are delivered to pharmaceutical companies, academic partners, and scientific collaborators through a network of 250+ German medical facilities and international cooperation under the GCIG umbrella.

Product overview

The AGO Study Group is a non-profit clinical research organization that designs and implements Phase I-III multicenter clinical trials for gynecological oncology indications. The organization provides comprehensive study services including study planning (biometrics, sample size calculation, monitoring plan), study implementation (document preparation, SAE/SUSAR management, monitoring), and study completion (final reports, publications, archiving). With over 250 participating medical facilities throughout Germany and international cooperation through the Gynecologic Cancer InterGroup (GCIG), the group focuses on ovarian, endometrial, cervical, and vulvar cancers. The services are offered as a unified clinical research service rather than a modular software product.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Services

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

13 partnerships are on record, tiered core, major and supporting.

• KKS Marburg (Coordinating Centre for Clinical Trials Marburg)coreImplementation/ SI/ Consulting PartnerBiometrics / Pharmacovigilance / Quality Management. The Coordinating Centre for Clinical Trials Marburg provides statistical and quality management support for AGO clinical trials.
• NOGGO (North-East German Society for Gynaecological Oncology)coreStrategic or Co-development PartnerNational cooperation partner for gynecological oncology research. AGO collaborates with NOGGO on various clinical trials and joint statements.
• ENGOT (European Network of Gynaecological Oncology Trials Groups)coreStrategic or Co-development PartnerEuropean Network of Gynaecological Oncological Trial groups. AGO leads the GCIG/ENGOT Intergroup Consortium for various international trials.
• GCIG (Gynecologic Cancer Intergroup)coreStrategic or Co-development PartnerGynecologic Cancer International Intergroup. AGO is part of the international network of academically oriented study groups under the GCIG umbrella, enabling worldwide integration of study centers.
• GINECO (Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens)coreStrategic or Co-development PartnerFrench gynecological oncology study group. Collaborates with AGO on numerous international clinical trials.
• EORTC (European Organisation for Research and Treatment of Cancer)majorStrategic or Co-development PartnerEuropean Organization for Research and Treatment of Cancer. International collaboration on gynecological cancer trials.
• AGO Kommission OvarcoreStrategic or Co-development PartnerAGO Ovarian Commission. National professional body focused on ovarian cancer guidelines and research.
• CCTG (Canadian Cancer Trials Group)majorStrategic or Co-development PartnerCanadian Cancer Trials Group. International partner for gynecological cancer clinical trials.
• NSGO (Nordic Society Gynecologic Oncology)majorStrategic or Co-development PartnerNordic Society Gynecologic Oncology. Scandinavian partner for clinical trials.
• GEICO (El Grupo Español de Investigación en Cáncer de Ovario)majorStrategic or Co-development PartnerSpanish Group for Investigation in Ovarian Cancer. European partner for ovarian cancer research.
• TMF (Technologie- und Methodenplattform für die vernetzte medizinische Forschung e.V.)supportingOthersTechnology and Methods Platform for Networked Medical Research. National partner for methodological support in clinical research.
• Schantl Pharma Service GmbHsupportingImplementation/ SI/ Consulting PartnerProvides monitoring services for clinical trials.
• MMF (MMF Research)supportingImplementation/ SI/ Consulting PartnerClinical Research Organisation providing additional research support services.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• NRG Oncology: The leading US gynecologic oncology cooperative group formed from the merger of GOG, NSABP, RTOG, and ACOSOG. Directly comparable to AGO as a nonprofit academic sponsor of Phase I-III gynecologic cancer trials, competing for global pharma-sponsored and intergroup studies.
• GINECO (Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens et du sein): France's national cooperative group for ovarian and breast cancer clinical research. Directly comparable to AGO as a country-level academic study group running Phase I-III gynecologic oncology trials within GCIG and ENGOT, often bidding against AGO for cross-border trials.
• CCTG (Canadian Cancer Trials Group): Canadian national cooperative oncology trials group. Comparable to AGO as an academic cooperative conducting Phase I-III trials (including gynecologic cancers) within the GCIG international network, competing for industry-sponsored studies.
• NOGGO (North-Eastern German Society of Gynecological Oncology): Berlin-based German cooperative group for gynecologic oncology. Directly comparable to AGO as a competing domestic German study group running parallel IITs and pharma-sponsored trials in the same indication, with overlapping hospital sites.
• ANZGOG (Australia New Zealand Gynaecological Oncology Group): Australia and New Zealand's gynecologic oncology cooperative group. Directly comparable to AGO as a regional academic study group within GCIG running Phase I-III trials in ovarian, endometrial, and cervical cancers across a defined national site network.
• MRC Clinical Trials Unit at UCL: UK academic clinical trials unit running large-scale Phase II/III cancer trials including in gynecologic oncology. Comparable to AGO in academic, non-commercial trial operations, statistical/methodological rigor, and pharma-IIT partnerships.
• GEICO (Grupo Español de Investigación en Cáncer de Ovario): Spanish cooperative group focused on ovarian and gynecologic cancer trials. Directly comparable to AGO as a national academic study group within ENGOT/GCIG running parallel ovarian and endometrial cancer trials targeting the same pharma sponsors.
• NSGO (Nordic Society of Gynecological Oncology): Scandinavian cooperative group for gynecologic oncology clinical trials. Directly comparable to AGO as a regional academic study group within ENGOT/GCIG running Phase II/III ovarian, uterine, and cervical cancer trials in a defined national site network.

Broad incumbents

• EORTC (European Organisation for Research and Treatment of Cancer): Pan-European academic clinical trials cooperative group with a dedicated Gynecological Cancer Group. Broad incumbent comparable to AGO in oncology trial infrastructure and pharma partnerships, but operating across many tumor types beyond gynecology.

Others

• BIG (Breast International Group): International academic cooperative group structure for oncology trials, organizationally comparable to AGO (non-profit, intergroup-sponsored trials, pharma-funded). Not a direct competitor in gynecologic oncology, but a structural template peer for academic cooperative trial operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ago-research-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AGO Study Group